Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

It’s critical that communities have access to prostate cancer care. Novartis is proud to announce its role as Lead Founding Partner of Blitz The Barriers. This initiative, spearheaded by prominent ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today ...